MIS416

I added MIS416 from Innate Therapeutics to the phase 2 list, based on this press release. It is particularly interesting to me for a couple of reasons: it is being tested for progressive MS, and Innate Therapeutics got some funding from US-based Fast Forward, which funds promising development-stage MS therapies.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: